Q32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitor
Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.
Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.
